Last updated: February 27, 2026
What is the Drug and Its Market Context?
NDC 64380-0163 refers to Wegovy (semaglutide), a GLP-1 receptor agonist approved by the FDA in June 2021 for the chronic weight management indication. It targets obesity and overweight patients with comorbidities, with an initial label dose of 2.4 mg weekly.
Wegovy's market entered a competitive landscape that includes other obesity drugs like Saxenda (liraglutide), Ozempic (semaglutide, for diabetes), and other emerging therapies.
Key Data Points
| Parameter |
Details |
| Manufacturer |
Novo Nordisk |
| Market Entry Year |
2021 |
| Approved Indications |
Obesity, weight management |
| Pricing (List Price) |
Approximately $1,350 per month (US retail) |
| Average Wholesale Price (AWP) |
Around $1,200 per month (US) |
| Medicaid/Insurance Coverage |
Variability; copays range from $0 to $50/month |
| Annual Market Size (2022) |
Estimated $1 billion globally |
| Projected 5-year CAGR |
20%+ |
Market Analysis
Demand Drivers
- Rising prevalence of obesity: US adult obesity at 42.4% (CDC, 2021).
- Increasing recognition of obesity as a chronic disease.
- Reimbursement pathways and brand awareness driven by Novo Nordisk's marketing.
- Growing acceptance of GLP-1 receptor agonists for weight management.
Competitive Landscape
| Drug |
Indication |
Price Range |
Market Share (2022) |
Notes |
| Wegovy |
Obesity |
~$1,350/month |
55% |
Blockbuster status, strong brand |
| Saxenda |
Obesity, Diabetes |
~$1,200/month |
20% |
Established, less potent than Wegovy |
| Ozempic |
Diabetes (off-label weight management) |
~$800/month |
15% |
Increased off-label use for weight loss |
| Other emerging drugs |
Obesity, weight loss |
Variable |
10% |
Pipeline products, biosimilars |
Market Trends
- Increasing adoption of weekly injectable GLP-1 drugs.
- Broader insurance coverage for obesity treatments.
- Expansion into Medicare and Medicaid covered populations.
- Growing international markets, notably in Europe and Asia.
Price Projections
Short-Term (1-2 Years)
- Expected stabilization of list prices around $1,350/month.
- Payer negotiations may reduce net prices by 10-20%.
- Insurance coverage expands, reducing patient out-of-pocket costs.
Medium-Term (3-5 Years)
- Possible price erosion due to biosimilar competition and marketplace saturation.
- Price reductions of 10-15% anticipated on wholesale and retail levels.
- Increased competition from new therapies or treatment combinations.
Long-Term (5+ Years)
- Introduction of biosimilars or generics could lower prices by 30-40%.
- Potential for value-based pricing models tied to outcomes.
- Market penetration in emerging regions may alter pricing strategies.
Revenue and Market Share Outlook
| Year |
Estimated Market Size |
Anticipated Market Share |
Projected Revenue (USD) |
| 2023 |
$1.2 billion |
55% (Wegovy) |
~$660 million |
| 2024 |
$1.4 billion |
60% |
~$840 million |
| 2025 |
$1.6 billion |
65% |
~$1.04 billion |
| 2026 |
$2 billion |
70% |
~$1.4 billion |
Risks and Opportunities
Risks
- Regulatory changes affecting pricing or reimbursement.
- Competitive entry from biosimilars or alternative modalities.
- Market saturation limiting growth.
Opportunities
- Expanding indications to pediatric populations.
- Developing oral formulations.
- Growing international markets with unmet needs.
Key Takeaways
- Wegovy commands a premium price point with stable demand driven by obesity prevalence.
- Market share remains robust amid competition; price erosion expected with biosimilar entrants.
- Reimbursement and insurance coverage significantly influence net profitability.
- International market expansion and pipeline development could sustain growth.
FAQs
1. What are the main factors influencing Wegovy’s market price?
Pricing is determined by manufacturing costs, competitor prices, reimbursement negotiations, and market demand.
2. How does insurance reimbursement impact the net price?
Coverage and copay structures can reduce out-of-pocket costs for patients, influencing net revenue.
3. Will biosimilars significantly lower Wegovy’s price?
Potentially, biosimilars could reduce prices by 30-40%, depending on market acceptance and patent challenges.
4. What future regulatory moves could affect pricing?
Price controls, value-based pricing models, or restrictions on off-label use can impact profitability.
5. Which international markets present growth opportunities?
Markets in Europe, Asia, and Latin America are expanding, with evolving reimbursement policies.
References
[1] CDC. (2021). Adult Obesity Facts. Centers for Disease Control and Prevention.
[2] IQVIA. (2022). The Global Use of Medicines in 2022.
[3] Novo Nordisk. (2021). Wegovy (semaglutide) prescribing information.
[4] HealthCare Market Insights. (2022). Obesity Pharmacotherapy Market Report.
